ROBERT HUTCHENSCHIEF EXECUTIVE OFFICER
Bob is a retired Partner of Booz & Company in New York. Booz & Company is a billion dollar management consulting firm with over 70 offices worldwide. Prior to Booz & Company Bob was a partner with the Management consulting firm of A.T. Kearney in New York.Bob has over 20 years of experience in management consulting. Most of his work has been with clients in the Life Sciences industry. His clients also included a number of major pharmaceutical companies as well as a range of medical device and supply companies.Bob also worked extensively with Centers for Disease Control (CDC) in Atlanta to redesign the supply chain and financial processes for the agency’s $4 billion Vaccine For Children (VFC) program. Additionally, Bob worked with the President’s Emergency Program For Aids Relief (PEPFAR) as well as with the Global Fund.Bob’s work with his clients addressed a range of topics including defining corporate strategies, developing market entry and launch strategies as well as working with these clients to improve the overall effectiveness of their organizations and operations. Bob holds a Bachelor of Business Administration from the Ross School of Business at The University of Michigan and he holds a Master of Business Administration from the Wharton School at the University of Pennsylvania.
MARK HORSEY
CHIEF FINANCIAL OFFICER
Mr. Horsey provides fractional Chief Financial Officer services to small and mid-sized life sciences firms in the San Antonio market. He has assisted multiple start-ups (Rapamycin Holdings, Cardiovate, and Bexar Medical) with financial model development, market validation, strategic financial planning, business plan creation, investor materials, capitalization and offering document assistance, as well as general accounting and operations support.Mr. Horsey began his consulting practice in October of 2011, and joined StemBioSys in September of 2012. Prior to joining StemBioSys, Mr. Horsey was with Genzyme Corporation in San Antonio, most recently serving as Director of Finance for San Antonio Operations and Genzyme’s multiple sclerosis business unit. Mr. Horsey was hand-selected as the financial lead for Genzyme’s multiple sclerosis business unit leadership team focused on the development and commercialization of LEMTRADA® (alemtuzumab) with full responsibility for the financial management of a $120m development program from phase II initiation through phase III and into pre-commercialization. Mr. Horsey led the team to achieve operational and budgetary goals for the duration of the program which culminated in the filing of a supplemental biologics license application to the FDA in June 2012.Prior to joining Genzyme, Mr. Horsey was Business Unit Controller for Dell Computer in Round Rock, Texas. In this role, he led all accounting and control activities for Dell Computer Corporation’s $14.1 billion U.S. Consumer and Small Business segment. Prior to Dell, Mr. Horsey held various leadership roles of increasing responsibility at Sears Roebuck and Company in the areas of accounting, finance, operations and sales.Mr. Horsey received his undergraduate degree in economics from the University of Texas at Austin, and an M.B.A. from Saint Edward’s University with a specialization in finance. Mr. Horsey has also recently completed a Financial Planning Certificate program through Northwestern University’s Kellogg School of Management.
SY GRIFFEY
CHIEF OPERATING OFFICER
Prior to joining StemBioSys, Dr. Griffey was with Kinetic Concepts (KCI) in San Antonio for over eight years, most recently serving as Senior Director in KCI’s Center for Advanced Research and Technology. Previous positions at KCI included Director, New Product Concept Development and Principal Scientist, Biosurgery Research.
Prior to joining KCI, Dr. Griffey spent 15 years with LifeCell Corporation (recently acquired by KCI) serving in various roles of increasing responsibility from basic research to new product concept development to product and process development. Dr. Griffey’s primary area of emphasis over 25+ years in industry R&D has been in assessing new ideas and technologies and evaluating the feasibility of turning these ideas into medical devices and products. His research and product development background includes programs and projects involving medical devices and tissue regeneration and biologic transplant materials for orthopedic, reconstructive, sports medicine and wound healing applications. Revenues generated from products that were directed by Dr. Griffey at various points in their development cycle are in the hundreds of millions per year.
Dr. Griffey received his bachelor’s and master’s degrees at Southwest Texas State University and received his doctorate from Baylor College of Medicine in Houston with a joint appointment in cell biology and biotechnology.
KEVIN BELGRADE
CHIEF MARKETING OFFICER
Kevin Belgrade is a chief marketing and communications officer with diverse experience driving change in some of the most disrupted industries of our time – including telecom and technology, health care and med-tech, and financial services.
Belgrade’s experience spans strategic marketing and channel strategy; customer experience; market research and analytics; product development; multi-channel campaigns; sales enablement; strategic communications; and organizational change. He has built and led B2B and B2C marketing and communications teams at multinational companies, mid-caps and start-ups; and he has extensive experience at the highest levels of organizational leadership and with corporate boards in public and private settings.
From 1999 to 2009, Belgrade was a Senior Vice President and Partner with Omnicom’s FleishmanHillard, where he served as a senior strategist to international clients. This period included a long-term assignment as an in-house executive for Texas-based AT&T. After his tenure at AT&T, Belgrade served as a Vice President and Corporate Officer of KCI, an Acelity Company, a $3B global medical device and med-tech company, and as Senior Vice President, Enterprise Marketing and Communications at CUNA Mutual Group, a $3B financial services company serving business customers and consumers.